Pharmaceutical major Lupin on Friday said it has received tentative approval for its cholesterol lowering Pitavastatin tablets from the US Food and Drug Administration (USFDA).
"Pharma Major Lupin announced today that it has received tentative approval for its Pitavastatin tablets, 1 mg, 2 mg and 4 mg from the United States Food and Drug Administration (FDA) to market a generic version of Kowa Company Limited's (Kowa) Livalo Tablets 1 mg, 2 mg and 4 mg," the pharmaceutical company said in a regulatory filing to the BSE.
"Pitavastatin tablets are indicated as an adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia," it added.
"Pharma Major Lupin announced today that it has received tentative approval for its Pitavastatin tablets, 1 mg, 2 mg and 4 mg from the United States Food and Drug Administration (FDA) to market a generic version of Kowa Company Limited's (Kowa) Livalo Tablets 1 mg, 2 mg and 4 mg," the pharmaceutical company said in a regulatory filing to the BSE.
"Pitavastatin tablets are indicated as an adjunctive therapy to diet to reduce elevated total cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia," it added.
Get real time advice for Stock Trading tips , Best Accurate Stock Tips , Stock Market Live , Equity Tips and all Maket Updates From Capitalstars .
Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
CapitalStars Investment Adviser: SEBI Registration Number: INA000001647
CapitalStars Investment Adviser: SEBI Registration Number: INA000001647
BOOK FULL PROFIT IN LT FOODS LIMITED, T2 ACHIEVED
ReplyDeleteFREE TRADING TIPS